Purpose

Gene fusions involving the IGH gene at 14q32 and MALT1 at 18q21 are frequent in several types of lymphoma. Such gene fusions have diagnostic and prognostic implications.

Clinical Utility

The presence of an IGH-MALT1 gene fusion supports a diagnosis of MALT lymphoma. The absence of such a fusion does not preclude this diagnosis.

This is an assay for non-heritable mutations. It does not raise issues of ethics or consent that are different from most other investigations ordered in the routine care of a patient.

Test Method

Fluorescent in situ hybridisation (FISH) analysis, using probes to identify fusion of IGH with MALT1, due to a t(14;18)(q32;q21) translocation.

Test Ordering

This test is usually requested by a haematologist or oncologist.

0.5 mL bone marrow in transport media or 10 mL blood in lithium heparin if clinically appropriate.

To help ensure the quality of the test, a genetic test should be done with a dedicated sample whenever possible i.e. a sample collected specifically for that test rather than a sample that is used for multiple tests.

We also recommend that the patient or another adult check the labelling of request forms and sample tubes.

Price

Pricing note:

The price varies according to the specific clinical conditions for a particular patient. Please contact Sonic Genetics on 1800 010 447 for more information.

Medicare Rebate

This test is not rebated by Medicare. The laboratory assumes that the patient or client has provided informed financial consent for the test.

Turnaround Time

2 working days.

For Doctors

For Patients